For the poly I:C-primed ASC group, an interesting mechanistic network differed from the LPS group in a predicted inhibition of Mitogen-Activated Protein Kinase 3/1 (ERK1/2), and in a stronger predicted inhibition of JUN, along with a predicted activation of Tumor Protein 53 (TP53), a key tumor-suppressor gene (Figure 8C). The gene discussed is MAP2K3; the disease is neoplasm.